About
TriFlo Cardiovascular Inc. is a biomedical company based in Southern California, founded in 2017. The company specializes in developing transcatheter solutions for treating tricuspid valve regurgitation, a condition where the tricuspid heart valve fails to close properly. Their main product, the TriFlo Tricuspid Flow Optimizer (TFO) System, aims to enhance valve function while maintaining the integrity of the valve leaflets and the contractility of the right ventricle. The team at TriFlo includes experienced professionals in cardiovascular device development, led by Co-Founder and CEO Luca Pesce, who has over 15 years of experience in transcatheter heart valve technologies. The company is focused on clinical development and is preparing for clinical trials of the TFO System, which features a unique anchoring mechanism designed to improve valve coaptation and reduce complications associated with existing surgical treatments. TriFlo Cardiovascular targets cardiovascular specialists, hospitals, and healthcare providers involved in minimally invasive cardiac interventions, aiming to provide effective solutions for patients with tricuspid valve disease.
Technologies
Keywords
Company Information
-
Employees 6
-
Founded 2017
-
Total Funding $685000
Location
20101 SW Birch St, Newport Beach, California, United States, 92660-0765
